At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Open +2 moredrug
Likely dose
Open 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
THE EFFECTS OF SITAXSENTAN ONCE DAILY DOSING ON PROTEINURIA, 24-HOUR BLOOD PRESSURE, AND ARTERIAL STIFFNESS IN SUBJECTS WITH CHRONIC KIDNEY DISEASE
In Brief
A Phase 2 clinical trial evaluating Open, Nifedipine, and 1 other intervention for Chronic Kidney Disease. Completed, enrolled 27 participants across 2 sites.
Detailed Summary
This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedDec 2008
Primary CompletionMar 2009
TodayJul 2026
First PostedDec 18, 2008
Enrollment StartMay 9, 2007
Primary CompletionMar 6, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.5 years ago
Interventions
Opendrug
Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
Nifedipinedrug
Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
Placebodrug
Placebo for sitaxsentan, orally administered once daily (double blind arm)